Using our Mitomic™ Technology, MDNA Life Sciences has developed an advanced portfolio of solutions for disease detection and prognosis. We currently have, or are developing, Mitomic™ Tests for the early detection of Prostate, Ovarian and Lung Cancers and Endometriosis.
In order to identify men who are most suitable for prostate biopsy, there is a need to identify a group at risk, not just of prostate cancer, but of significant prostate cancer.
The Mitomic™ Prostate Test from MDNA is the most accurate way of determining if a patient is at risk of having clinically significant prostate cancer, outperforming every other test on the market with just a simple blood test. Its high negative predictive value for clinically significant cancer enables more accurate and informed biopsy decisions.
176 million women worldwide suffer from endometriosis, a disease that is notoriously difficult to diagnose
MET is the first ever non-invasive blood-based test. It identifies the 8.7kb mitochondrial DNA deletion, a new and accurate biomarker of endometriosis with the potential to significantly reduce the diagnostic delay and stall disease progression with earlier intervention.
176 million women worldwide suffer from endometriosis, a disease that is notoriously difficult to diagnose
At MDNA Life Sciences we’re constantly working on bringing new, highly accurate tests to market for hard to diagnose diseases. Mitomic™ Tests are currently in development for the early detection of Endometriosis and Ovarian, Lung, Liver, Pancreatic and Stomach Cancers.